Table 1 displays currently active or recently completed clinical trials in HPV-associated OPSCC (adapted from https://clinicaltrials.gov)

1

NCT03656133

Use of a Proliferation Saturation Index to Determine Personalized

Radiotherapy for HPV + Oropharyngeal Cancers

• Radiotherapy fractionation

2

NCT03618134

Stereotactic Body Radiation Therapy and Durvalumab With or

Without Tremelimumab Before Surgery in Treating Participants

With Human Papillomavirus Positive Oropharyngeal Squamous Cell

Caner

• Durvalumab

• Modified Radical Neck Dissection

• Transoral Robotic Surgery

• Tremelimumab

3

NCT03580070

Changes in the Microenvironment of HPV-induced Head and Neck

Cancers in West Indies and Metropolitan Population

• Immunotherapy

4

NCT03578406

HPV-E6-Specific TCR-T Cells in the Treatment of HPV-Positive

NHSCC or Cervical Cancer

• HPV E6-specific TCR-T cells

5

NCT03418480

HPV Anti-CD40 RNA Vaccine

• HPV vaccine

6

NCT03396718

De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive

Head-neck Squamous Cell Carcinomas

• De-escalation radio(chemo)therapy

- Levels 1 and 2

7

NCT03342911

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

• Paclitaxel, Carboplatin, Nivolumab

8

NCT03260023

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN

• TG4001, Avelumab

9

NCT03224000

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

• Modified Barium Swallow, MRI

Guided Intensity Modulated Radiotherapy

10

NCT03162224

Safety and Efficacy of MEDI0457 and Durvalumab in Patients With

HPV Associated Recurrent/Metastatic Head and Neck Cancer

• MEDI0457, CELLECTRA®5P

device, Durvalumab

11

NCT03107182

Chemotherapy and Locoregional Therapy Trial (Surgery or

Radiation) for Patients With Head and Neck Cancer

•Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine,

Paclitaxel

12

NCT03077243

P53 Mutational Status and cf HPV DNA for the Management of

HPV-associated OPSCC

• Intensity Modulated Radiotherapy,

Cisplatin (or alternative)

13

NCT02945631

Quarterback 2 - Sequential Therapy With Reduced Dose

Chemoradiotherapy for HPV Oropharynx Cancer

• Radiation: PTV56

14

NCT02865135

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV

16-Related Oropharyngeal, Cervical And Anal Cancer

• DPX-E7 vaccine

15

NCT02827838

Durvalumab Before Surgery in Treating Patients With Oral Cavity or

Oropharynx Cancer

• Durvalumab

16

NCT02784288

Phase II Treatment Stratification Trial Using Neck Dissection-Driven

Selection to Improve Quality of Life for Low Risk Patients With HPV

+ Oropharyngeal Squamous Cell Cancer

•Radiation, Carboplatin, Paclitaxel

17

NCT02706691

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

•BGJ398

18

NCT02686008

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

• Olaparib

19

NCT02643550

Study of Monalizumab and Cetuximab in Patients With Recurrent or

Metastatic Squamous Cell Carcinoma of the Head and Neck

• Monalizumab, Cetuximab

20

NCT02281955

De-intensification of Radiation and Chemotherapy for Low-Risk

HPV-related Oropharyngeal SCC: Follow-up Study

• Radiation, cisplatin

21

NCT02215265

Post-operative Adjuvant Treatment for HPV-positive Tumours

(PATHOS)

• Cisplatin, Postoperative radiotherapy

22

NCT02178072

Window Trial 5-aza in HNSCC, T-tare

• 5-Azacitadine

23

NCT02113878

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk

Locally Advanced Squamous Cell Cancer of Head and Neck

• BKM120, Cisplatin, Intensity-modulated radiotherapy

24

NCT02002182

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive

Oropharyngeal Cancer

• ADXS11–001 (ADXS-HPV)

25

NCT01716195

Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer

• Radiotherapy

26

NCT01706939

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

• Reduced Dose Radiation, Carboplatin

27

NCT01530997

De-intensification of Radiation & Chemotherapy in Low-Risk Human

Papillomavirus-related Oropharyngeal Squamous Cell Ca

• Intensity Modulated Radiotherapy, Cisplatin

28

NCT01302834

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients

With Oropharyngeal Cancer

• cetuximab, cisplatin